A toilet-seat based cardiovascular monitoring system aims to lower the hospital readmission rates of patients with congestive heart failure. The toilet seats, which would be purchased by hospitals and issued to heart failure patients after discharge, are equipped to measure the electrical and mechanical activity of the heart, and can monitor heart rate, blood pressure, blood oxygenation levels, and the patient’s weight and stroke volume.
Algorithms analyze the data, and with further development, will alert advanced practice providers of a deteriorating condition. A report will be passed along to cardiologists who will then determine if intervention is necessary. The system will pick up deteriorating conditions before the patients even realize they are symptomatic. And with the rapid data analysis, interventions can be as simple as a drug change or short office visit, instead of an admission to the hospital.
Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, which will take the product through the FDA clearance process, is part of the university team that developed the toilet seats.
“Typically, within 30 days of hospital discharge, 25 percent of patients with congestive heart failure are readmitted,” says Conn. “After 90 days of hospital discharge, 45 percent of patients are readmitted. And the Centers for Medicare and Medicaid Services is penalizing hospitals for readmitting patients for heart failure.”
Conn further explains that using the national average for readmission rates, the penalty alone for readmitting 150 patients is approximately $500,000 annually. The total cost of providing 150 patients with their own monitored toilet seats from HHI is $200,000. With that investment, he says, hospital systems will save more than double their initial investment within one year.
HHI, which joined RIT’s Venture Creations business incubator earlier this year, is now focused on moving the product forward. The team is heavily involved in writing grants for additional funding and networking, and human-subject testing and pre-clinical studies are well underway. Conn and his team are working on approving the product with the FDA and rolling it out across the country.